Wall Street Zen Downgrades Cencora (NYSE:COR) to Hold

by · The Cerbat Gem

Cencora (NYSE:COR – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Friday.

Other equities analysts have also issued research reports about the stock. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. UBS Group upped their price target on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research note on Tuesday. TD Cowen boosted their price objective on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Finally, Mizuho upped their target price on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $371.09.

Check Out Our Latest Stock Analysis on Cencora

Cencora Trading Up 0.1%

Shares of Cencora stock traded up $0.40 on Friday, reaching $368.93. 656,118 shares of the company’s stock were exchanged, compared to its average volume of 1,540,059. The company has a market capitalization of $71.53 billion, a P/E ratio of 37.96, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora has a 52 week low of $223.92 and a 52 week high of $377.54. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The firm’s 50-day moving average is $335.71 and its two-hundred day moving average is $307.44.

Cencora (NYSE:COR – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. Cencora’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 46,640 shares of company stock worth $14,099,338. 10.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC boosted its holdings in Cencora by 31.4% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company’s stock worth $43,000 after purchasing an additional 33 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Cencora during the 3rd quarter worth approximately $8,327,000. Achmea Investment Management B.V. boosted its stake in shares of Cencora by 1.0% in the 3rd quarter. Achmea Investment Management B.V. now owns 112,575 shares of the company’s stock worth $35,183,000 after buying an additional 1,071 shares during the last quarter. Centaurus Financial Inc. grew its holdings in shares of Cencora by 26.0% in the third quarter. Centaurus Financial Inc. now owns 3,494 shares of the company’s stock valued at $1,092,000 after acquiring an additional 722 shares in the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Cencora during the third quarter valued at approximately $95,614,000. 97.52% of the stock is owned by institutional investors.

About Cencora

(Get Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Recommended Stories